Solgen Company Profile
What is the competitive landscape for SOLGEN
SOLGEN has five approved drugs.
Summary for Solgen
| US Patents: | 0 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Solgen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solgen | DEXAMETHASONE | dexamethasone | TABLET;ORAL | 218372-002 | Sep 17, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solgen | RAMIPRIL | ramipril | CAPSULE;ORAL | 079116-002 | Jun 20, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solgen | DEXAMETHASONE | dexamethasone | TABLET;ORAL | 218372-004 | Sep 17, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solgen | PIOGLITAZONE HYDROCHLORIDE | pioglitazone hydrochloride | TABLET;ORAL | 210165-001 | Jan 22, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
